U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
965 articles with Allergan, Inc.
Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
One-year study continues to support positive safety and tolerability profile for ubrogepant
FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360's Supplemental New Drug Application
10/15/2018Depression affects almost 20 million Americans yearly and major depressive disorders affect nearly 300 million people worldwide. The annual market for these disorders is approximately $83 billion.
Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14. The meeting will be held at the JW Marriott Desert Ridge Resort &
Allergan, a leading global pharmaceutical company, has joined the TriNetX global health research network for real-time access to patient populations, driven and refreshed by clinical data, to determine protocol feasibility, cohort analysis and site identification.
Allergan Presents New Research at the American College of Gastroenterology Annual Scientific Meeting (ACG 2018)
American College of Gastroenterology Annual Scientific Meeting (ACG), from October 5-10, 2018 in Philadelphia, PA.
Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease
New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab
FDA clearance was expanded to include patients with a BMI of up to 46.2 when treating the submental and submandibular areas.
Bigger, bolder JUVÉDERM® campaign seeks to make JUVÉDERM® a household name for consumers
Pfizer announced its succession plan for when Ian Read steps down as chief executive officer on January 1, 2019. The new chief executive officer will be Albert Bourla, who is currently the company’s chief operating officer.
Allergan plc today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.S. financial markets.
Allergan Foundation pledges $2,000,000 to support breast health research
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
- Application Seeks to Expand VRAYLAR Indication to Include the Treatment of Bipolar Depression
lmirall, S.A.(ALM) announced today the finalization of their acquisition of products from Allergan's Medical Dermatology unit in the United States: Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (flurandrenolide).
Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st
The company and actor join forces to pay homage to those affected by Alzheimer's Disease
Allergan and its development partner Sosei Group have voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
In a 99 to 1 vote, the Senate passed the bill that looks to cut down on the flow of illegal narcotics entering the United States through the mail, as well as taking aim at the abuse of prescription opioid medication – a problem that has grown to an epidemic in the United States.
Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines
Study met primary endpoint demonstrating that higher doses of BOTOX® Cosmetic produce greater duration of treatment effect